**Background:** Retinal detachment (RD) deprives the neurosensory retina of oxygen and nutrients, leading to hypoxia, oxidative stress, inflammation, and apoptosis. Surgical reattachment is the only treatment, but delays of up to several weeks are common, and no pharmacological intervention exists to protect the retina during this waiting period. Green tea extract (GTE) has known anti-oxidative, anti-inflammatory, and anti-apoptotic properties. This study investigated whether oral GTE could mitigate retinal damage in a rat RD model.
**Methods:** Retinal detachment was induced in female Sprague Dawley rats by subretinal injection of 2 µL of 1% sodium hyaluronate. Four hours later, rats received oral GTE (Theaphenon E®, containing 70% EGCG) at various doses twice daily for three days. Two batches were tested: Batch 1 compared non-RD, RD, GTE 142.9 mg/kg (96.3 mg/kg EGCG), EGCG 96.3 mg/kg, and EGCG 352.2 mg/kg; Batch 2 compared non-RD, RD, GTE 275 mg/kg (185.3 mg/kg EGCG), and GTE 550 mg/kg (370.6 mg/kg EGCG). Outcomes included electroretinography (ERG) scotopic and photopic a- and b-wave amplitudes, normalized outer nuclear layer (ONL) thickness (using INL as control), TUNEL staining for apoptosis, ELISA for caspase-3, sphingomyelin, protein carbonyl, and HIF-1α, cytokine array of vitreous humor, and GC/MS for retinal fatty acid and cholesterol levels.
**Key Results:** The low dose of GTE (142.9 mg/kg) showed significant protective effects. Normalized ONL thickness was significantly reduced compared to RD (82.4 ± 8.2% of RD in Batch 1, p < 0.05; 66.0 ± 8.2% in Batch 2, p < 0.05), approaching non-RD levels (83.5 ± 4.7%). ERG scotopic a- and b-wave amplitudes and photopic b-wave amplitude were significantly higher in the low-dose GTE group than in RD (p < 0.05), with scotopic a-wave and photopic b-wave amplitudes similar to non-RD. Higher GTE doses (275 and 550 mg/kg) and EGCG alone (96.3 and 352.2 mg/kg) did not improve ERG amplitudes and sometimes worsened them. TUNEL-positive cells were significantly reduced in the low-dose GTE group compared to RD (p < 0.0001). Caspase-3 levels remained elevated in the GTE group, but sphingomyelin levels were significantly decreased (p < 0.05). Protein carbonyl content (oxidative stress marker) and HIF-1α levels were significantly lower in the GTE group than in RD (p < 0.05). Cytokine array revealed that RD increased pro-inflammatory cytokines (CCL2, CCL20), GDF-15, OPN, MMP3, serpin E1, and metabolic regulators (adiponectin, DPPIV, IGF-1, IGFBP-3) by >2.5-fold. GTE treatment significantly reduced CCL2, serpin E1, adiponectin, DPPIV, IGF-1, and IGFBP-3, while increasing IL-13 and IL-1α. Free fatty acids increased >30-fold after RD, but GTE did not significantly alter this. Cholesterol levels did not differ among groups.
**Clinical Implications:** This study provides the first evidence that oral GTE can protect the retina during the critical three-day window after RD, preserving function and structure. The effective dose (142.9 mg/kg in rats) corresponds to approximately 0.984 g EGCG equivalent twice daily in humans, which is below the well-tolerated dose in phase II clinical trials. GTE's mechanisms include anti-oxidation (reducing protein carbonyl and HIF-1α), anti-inflammation (suppressing CCL2, increasing IL-13), anti-apoptosis (reducing sphingomyelin and TUNEL-positive cells), and metabolic modulation (lowering adiponectin, DPPIV, IGF-1). These findings suggest GTE could be a safe, readily available oral supplement to minimize retinal damage while patients await surgery, potentially improving visual outcomes. Further clinical studies are warranted.